KRAS and neoplasm: Ixazomib concentrations in KRAS mutant tumors were either similar to or higher than those in KRAS WT tumors (Fig 1B), and tumor proteasome β5-site activity was inhibited to a similar degree in both KRAS wild type and mutant tumors (Fig 1C).